Dr. Jordan goes to DC: Father of tamoxifen joins Lombardi

Publication
Article
Oncology NEWS Today BlogOncology NEWS Today Blog Vol 18 No 5
Volume 18
Issue 5

V. Craig Jordan, OBE, PhD, DSc, will become the scientific director for the cancer center and vice chairman of the department of oncology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center.

V. Craig Jordan, OBE, PhD, DSc, will become the scientific director for the cancer center and vice chairman of the department of oncology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center.

Dr. Jordan will take up his post at the Washington, DC-based institutions in July. He will also occupy an endowed chair. Dr. Jordan currently serves as vice president and scientific director for the medical sciences at Fox Chase Cancer Center in Philadelphia, where he holds the Alfred G. Knudson Jr., MD, PhD, Chair in Cancer Research. Dr. Jordan is also an adjunct professor of cancer biology at the University of Pennsylvania and a visiting professor of molecular medicine at the University of Leeds in England.

To learn more about Dr. Jordan’s life and career in “Father of tamoxifen a Brit to the core,” May 2008, visit www.cancernetwork.com

Recent Videos
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Related Content